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This research describes the development of a new multiplex real-time RT-PCR test for detection of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with primers designed to amplify a 108 bp
target on the spike surface glycoprotein (S gene) and a hydrolysis TaqMan probe designed to speciﬁcally
detect SARS-CoV-2. The limit of detection (LOD) and clinical performance of this new assay were
evaluated. A LOD study with inactivated virus exhibited performance equal to the modiﬁed CDC assay,
with a ﬁnal LOD of 1301  13 genome equivalents/mL for the Northwell Health Laboratories laboratorydeveloped test (NWHL LDT) versus 1249  14 genome equivalents/mL for the modiﬁed CDC assay. In
addition, a clinical evaluation with 270 nasopharyngeal swab specimens exhibited 98.5% positive
percent agreement and 99.3% negative percent agreement compared with the modiﬁed CDC assay. The
NWHL LDT multiplex design allows testing of 91 patients per plate, versus a maximum of 29 patients per
plate on the modiﬁed CDC assay, providing the beneﬁt of testing signiﬁcantly more patients per run and
saving reagents, during a time when both of these parameters are critical. The results show that the
NWHL LDT multiplex assay performs as well as the modiﬁed CDC assay but is more efﬁcient and costeffective and can be used as a diagnostic assay and for epidemiologic surveillance and clinical management of SARS-CoV-2. (J Mol Diagn 2020, -: 1e6; https://doi.org/10.1016/j.jmoldx.2020.09.004)

Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) was ﬁrst discovered as an etiologic agent of coronavirus disease 2019 (COVID-19) in the city of Wuhan,
Hubei Province, China, by the end of December 2019.1 It is
the seventh coronavirus known to infect humans and also to
be transmitted from human to human. The four seasonal
coronaviruses (HKU1, NL63, OC43, and 229E) are associated with mild symptoms, whereas SARS-CoV, Middle
East respiratory syndrome-related coronavirus, and SARSCoV-2 can cause severe acute respiratory disease.2,3
SARS-CoV-2 belongs to the Betacoronavirus genus and is
an enveloped, single-strand RNA virus with an approximately 29.8 kb genome, which can cause a wide range of
clinical presentations from asymptomatic or mild illness to
fatal outcomes.4,5 Thus far, COVID-19 has resulted in a
dramatic loss of lives globally; infections and deaths are
being tracked by the COVID-19 Dashboard by the Center
for Systems Science and Engineering at Johns Hopkins

University
(https://www.arcgis.com/apps/opsdashboard/
index.html#/bda7594740fd40299423467b48e9ecf6).
Furthermore, the symptoms of patients with COVID-19 can
be similar to those of patients with other seasonal respiratory
infections. Presently, there are no available speciﬁc therapeutics or vaccinations against COVID-19, making early
and accurate diagnosis for this very contagious disease the
key mitigation strategy.
Nucleic acid ampliﬁcation testebased assays for detection of SARS-CoV-2 in respiratory specimens have been the
standard diagnostic method. To date, the US Food and Drug
Administration has issued 107 laboratory-developed
COVID-19
molecular
assays
Emergency
Use
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Authorization (US Food and Drug Administration, https://
www.fda.gov/medical-devices/coronavirus-disease-2019covid-19-emergency-use-authorizations-medical-devices/
vitro-diagnostics-euas, last accessed July 13, 2020). The
US CDC developed a SARS-CoV-2 assay that was
initially the most widely used. This assay includes primers
and probes to detect the N1 and N2 regions of the nucleocapsid gene and also the human RNase P gene to monitor
RNA extraction and ensure specimen quality. The modiﬁed
CDC assay has been shown to have high analytical sensitivity and ideal clinical performance compared with three
commercially available COVID-19 diagnostic platforms
issued Emergency Use Authorization status by the US Food
and Drug Administration.6
The aim of the current study was to develop and evaluate the
analytical sensitivity and clinical performance of an efﬁcient
and cost-effective test on the Applied Biosystems 7500 Fast Dx
Real-Time PCR Instrument (Thermo Fisher Scientiﬁc, Waltham, MA). To that end, the Northwell Health Laboratories
laboratory-developed test (NWHL LDT) was developed to
target the S gene of SARS-CoV-2, and its clinical performance
compared with that of the modiﬁed CDC assay for the detection
of SARS-CoV-2 in nasopharyngeal (NP) specimens from individuals suspected of having COVID-19.

by Integrated DNA Technologies, Inc. (Coralville, IA). In
addition, the primers and probe of the human RNase P gene
used for the assay internal control were also synthesized by
Integrated DNA Technologies, Inc., and were the same sequences used in the CDC assay (v3) for this gene target
(CDC, https://www.cdc.gov/coronavirus/2019-nCoV/lab/
index.html, last accessed July 13, 2020). Here, the 50 base
of the probe of the RNase P gene was modiﬁed and
labeled with Cy5, and the 30 base of the probe was
labeled with Black Hole Quencher 2 to allow multiplexing
of the assay.

Materials and Methods

In this one-step, real-time qualitative RT-PCR assay, a
TaqPath 1-step real-time quantitative PCR kit (catalog
number A15299; Thermo Fisher Scientiﬁc) was used to
perform cDNA synthesis and PCR ampliﬁcation on the 96well plate at a 20 mL ﬁnal reaction volume. After the PCR
condition was optimized, the PCR reaction mix contained 5
mL of 4 RT-PCR Master Mix, 0.72 mL of S gene forward
primer at 25 mmol/L, 0.72 mL of S gene reverse primer at 25
mmol/L, 0.16 mL of S gene probe at 25 mmol/L, 0.64 mL of
RNase P gene forward primer at 25 mmol/L, 0.64 mL of
RNase P gene reverse primer at 25 mmol/L, 0.16 mL of
RNase P probe at 25 mmol/L, 6.96 mL of nuclease-free
water, and 5 mL of extracted RNA. The thermal cycler
proﬁle consisted of 25 C for 2 minutes, 50 C for 15 minutes, and 95 C for 2 minutes, followed by 45 cycles at
95 C for 3 seconds and 55 C for 30 seconds; this was
conducted on the 7500 Fast Dx Real-Time PCR Instrument.

Primers and Probe Design
Available whole-genome sequence of SARS-CoV-2 (as of
February 27, 2020) retrieved from the National Center for
Biotechnology Information GenBank database (https://
www.ncbi.nlm.nih.gov/nuccore/?term=SARS-CoV-2) and
the Global Initiative on Sharing All Inﬂuenza Database
were aligned by using Clustal Omega software from
EMBL-EBI (Wellcome Trust Genome Campus, Hinxton,
Cambridgeshire, UK). The designed primers and probe
exhibited 100% similarity with the targeted region of the
S gene of all SARS-CoV-2 genome sequences only
(Table 1). The primers and probe were designed by using
Primer Express software version 3.0 (Thermo Fisher Scientiﬁc) in the S gene of SARS-CoV-2 and were synthesized
Table 1

RNA Extraction
Total RNA was extracted from 110 mL of patient NP specimen
collected in 3 mL of viral transport medium or 110 mL of
contrived specimen from the serial dilutions panel by the
NucliSENS easyMag platform (BioMérieux, Durham, NC)
according to the manufacturer’s instructions; the ﬁnal elution
volume was 110 mL. To monitor the extraction process, a
negative extraction control was included in each extraction
run; the RNase P target must be detected from this control.

NWHL LDT

Real-Time RT-PCR Primer/Probe Set of S Gene Target for Speciﬁc Detection of SARS-CoV-2 and Primer/Probe Set of RNase P Gene

Target

Name

Sequence*

Nucleotide position

S

S Gene-Fwd
S Gene-Rev
S Gene-Probe
RP-Fwd
RP-Rev
RP-Probe

50 -TCAACTCAGGACTTGTTCTTAC-30
50 -TGGTAGGACAGGGTTATCAAAC-30
50 -FAM-TGGTCCCAGAGACATGTATAGCAT-BHQ1-30 y
50 -AGATTTGGACCTGCGAGCG-30
50 -GAGCGGCTGTCTCCACAAGT-30
50 -Cy5-TTCTGACCTGAAGGCTCTGCGCG-BHQ2-30 z

21,710w21,731
21,796w21,817
21,759w21,782

RNase P

*The nucleotide numbering is based on that of the curated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) whole-genome sequence
(GenBank, https://www.ncbi.nlm.nih.gov/nuccore; accession number MN908947.3).
y
The 50 base of the S gene probe was labeled with FAM, and the 30 base of the probe was labeled with Black Hole Quencher 1.
z
The 50 base of the probe of the RNase P gene was labeled with Cy5, and the 30 base of the probe was labeled with Black Hole Quencher 2.
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Table 2

Summary of LOD Results
No. of replicates detected/total no. of replicates at each dilution
expressed by GE/mL (% positive rate)

Molecular assay

Target 4000 2000

NWHL LDT
S
Modiﬁed CDC assay N1
N2

4/4
4/4
4/4

1000

500

250

125

Probit
(95% CI),* GE/mL Final LOD,y GE/mL

6/6 (100) 9/10 (90) 5/10 (50) 2/8 (25) 1/8 (25) 1301  13
6/6 (100) 9/10 (90) 7/10 (70) 6/8 (75) 1/8 (25) 1249  14
6/6 (100) 10/10 (100) 5/10 (50) 2/8 (25) 1/8 (25) 946  11

1301  13
1249  14

*Upper/lower () 95% CI.
y
The ﬁnal LODs were based on both assays’ results interpretation algorithm and determined by using probit analysis.
GE/mL, genome equivalents/mL; LOD, limit of detection; NWHL LDT, Northwell Health Laboratories laboratory-developed test.

Each run included a No Template Control, a Negative
Extraction Control, and a SARS-CoV-2epositive control. In
this study, a Negative Extraction Control was prepared by
suspending a noninfectious human HEL cell line (provided
by the New York State Department of Health) into a prealiquoted 2 mL lysis tube; a SARS-CoV-2 RNA transcript
(SARS-CoV-2 standard) containing ﬁve genes (E, N, S,
ORF1ab, and RdRP), with a titer of 200,000 copies/mL for
each gene from Exact Diagnostics (catalog number
COVID19; Fort Worth, TX), was diluted with extracted
nucleic acid from human specimens to make a SARS-CoV2epositive control. The ﬁnal concentration of SARS-CoV-2
with 50,000 copies/mL was aliquoted into 30 mL of a
nuclease-free tube and stored at 70 C to 80 C freezer for
use. The NWHL LDT used the same RT-PCR reagents and
conditions as the modiﬁed CDC assay, except for the target
primer and probe.

Analytical Sensitivity (Limit of Detection)
Limit of detection (LOD) was determined by extracting and
testing serial dilutions of quantiﬁed inactivated SARS-CoV2 from Isolate USA-WA1/2020 (NR-52287, BEI Resources,
Manassas, VA). SARS-CoV-2 viral material was provided
at a concentration of 4.1  109 genome equivalents (GE)/
mL, from which the following serial dilutions were prepared
in GE/mL: 4000, 2000, 1000, 500, 250, and 125. Ambion
RNA Storage Solution (catalog number AM7001; Thermo
Fisher Scientiﬁc) was used to prevent the potential RNA
degradation, and replicates ranging from 4 to 10 at each
dilution went through nucleic acid extraction on different
days and were tested on both the modiﬁed CDC assay and
the NWHL LDT. LOD was deﬁned as the concentration of
the lowest dilution that can be detected with >95% probability and was determined by using probit analysis.

Analytical Speciﬁcity
The speciﬁcity of the NWHL LDT primers and probe for
SARS-CoV-2 detection was evaluated by using in silico
analysis and by testing a SARS-CoV control with a concentration of 20,000 RNA transcript copies/mL (GenBank,
https://www.ncbi.nlm.nih.gov/nuccorea; accession number
MG772933.1) (catalog number 10006624; Integrated
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DNA Technologies, Inc.), Middle East respiratory
syndromeerelated coronavirus control with concentration
of 20,000 RNA transcript copies/mL (GenBank, https://
www.ncbi.nlm.nih.gov/nuccore;
accession
number
MK796425.1) (catalog number 10006623; Integrated
DNA Technologies, Inc.), and clinical specimens positive
for respiratory pathogens (n Z 41) covering coronavirus
(229E, NL63, OC43, and HKU1), inﬂuenza A H3,
inﬂuenza B, 2009 H1N1, respiratory syncytial virus A,
respiratory syncytial virus B, parainﬂuenza virus type 1 to
4, human metapneumovirus, adenovirus, Mycoplasma
pneumoniae, and Chlamydia pneumoniae; these were
initially identiﬁed by using a multiplex respiratory panel
between October 2018 and December 2019 at NWHL.

Study Design
A modiﬁed version (v3) of the CDC assay was used as a
reference method in this study. A total of 270 NP specimens
Table 3 Respiratory Pathogens Included in the Analytical
Speciﬁcity Assessment
Respiratory pathogens tested

SARS-CoV-2 result

SARS-CoV (MG772933.1)
MERS-CoV (MK796425.1)
Human coronavirus 229E (n Z 4)
Human coronavirus HKU-1 (n Z 4)
Human coronavirus NL63 (n Z 4)
Human coronavirus OC43 (n Z 4)
Adenovirus (n Z 2)
Enterovirus/rhinovirus (n Z 2)
Human metapneumovirus (n Z 2)
Inﬂuenza A H1-2009 (n Z 2)
Inﬂuenza A H3 (n Z 2)
Inﬂuenza B (n Z 2)
Parainﬂuenza virus 1 (n Z 1)
Parainﬂuenza virus 2 (n Z 1)
Parainﬂuenza virus 3 (n Z 1)
Parainﬂuenza virus 4 (n Z 2)
Respiratory syncytial virus A (n Z 2)
Respiratory syncytial virus B (n Z 2)
Chlamydia pneumoniae (n Z 2)
Mycoplasma pneumoniae (n Z 2)

Not
Not
Not
Not
Not
Not
Not
Not
Not
Not
Not
Not
Not
Not
Not
Not
Not
Not
Not
Not

detected
detected
detected
detected
detected
detected
detected
detected
detected
detected
detected
detected
detected
detected
detected
detected
detected
detected
detected
detected

MERS-CoV, Middle East respiratory syndrome-related coronavirus; SARSCoV-2, severe acute respiratory syndrome coronavirus 2.
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Table 4

Clinical Performance Comparison between the NWHL LDT and Modiﬁed CDC Assay for the Detection of SARS-CoV-2 RNA (n Z 270)
Modiﬁed CDC assay

NWHL LDT

Detected

Not detected

Kappa (95% CI)*

PPA (95% CI)*

NPA (95% CI)*

Detected
Not detected

128
2

1
139

0.978 (0.953e1.0)

98.5% (0.946e0.996)

99.3% (0.961e0.999)

*Upper/lower () 95% CI.
NPA, percent negative agreement; NWHL LDT, Northwell Health Laboratories laboratory-developed test; PPA, percent positive agreement; SARS-CoV-2,
severe acute respiratory syndrome coronavirus 2.

(130 positive and 140 negative specimens) originally submitted for SARS-CoV-2 testing at NWHL between March
and April 2020 were selected for this study. The 270
specimens were initially tested by using the modiﬁed CDC
assay, and extracted RNA was stored at 80 C until testing
with the NWHL LDT was performed; all NP specimens
after the CDC assay were aliquoted and kept in a freezer at
80 C. The specimens were selected as any consecutive
specimen that was performed on the modiﬁed CDC assay
and represented the true positivity rate (approximately 50%)
during the time frame of this study, comprising positive
specimens spanning the range of positivity levels. These
specimens included 24 with low viral load characterized by
a high cycle threshold (Ct) value in the range of 31.7 to 39.7
according to the modiﬁed CDC assay. For discordant results, a new RNA extraction was performed from stored,
frozen (80 C) specimens, and testing was repeated on
both assays. This study was performed to validate the
NWHL LDT for clinical use.

Statistical Methods
The ﬁnal result interpretation algorithm for reporting a
positive specimen requires both N1 and N2 targets to be
detected in the modiﬁed CDC assay, and both the modiﬁed
CDC assay and the NWHL LDT use a Ct <40 as the criterion for positivity. Percent positive agreement, percent
negative agreement, kappa analysis, and two-sided (upper/
lower) 95% CI were calculated by using Microsoft Ofﬁce
Excel 365 MSO Professional Plus 2013 software (Microsoft, Redmond, WA). As a measure of overall agreement,
Cohen’s kappa values were calculated, with values categorized as follows: >0.90 Z almost perfect, 0.90 to
0.80 Z strong, 0.79 to 0.60 Z moderate, 0.59 to
0.40 Z weak, 0.39 to 0.21 Z minimal, and 0.20 to
0 Z none.7,8

Results

set. The primers and probe designed for S gene detection
were conceived by using all available SARS-CoV-2
whole-genome sequences. The analysis of sequence alignments revealed that the region of the S gene of SARS-CoV2 targeted by the designed primer and probe set had 100%
similarity with all available SARS-CoV-2 whole-genome
sequences from the GenBank database and the Global
Initiative on Sharing All Inﬂuenza Database at the time of
development. When the S gene of other coronaviruses was
analyzed, including SARS-CoV, Middle East respiratory
syndromeerelated coronavirus, the four seasonal coronaviruses (HKU1, OC43, NL63, and 229E), and bat RaTG13,
the closest match to SARS-CoV-2 (which was bat RaTG13)
had a total of eight nucleotide mismatches with the NWHL
primer/probe set, indicating that this design is highly speciﬁc for SARS-CoV-2.

Analytical Sensitivity
The LOD of the NWHL LDT was 1301  13 GE/mL for the
S gene target. For the modiﬁed CDC assay, the LOD was
1249  14 GE/mL for the N1 target and 946  11 GE/mL
for the N2 target (Table 2). The ﬁnal LOD of the modiﬁed
CDC assay was 1249  14 GE/mL in accordance with the
result interpretation algorithm.

Analytical Speciﬁcity
In silico analysis and blastn analysis were performed against
the standard and betacoronavirus database of the National
Center for Biotechnology Information, and results showed
no cross-reactivity with other respiratory pathogens. Clinical
specimens positive for respiratory pathogens were also
tested to further evaluate the speciﬁcity of the NWHL LDT.
According to the results shown in Table 3, a speciﬁcity of
100% was achieved, with the NWHL LDT exhibiting no
cross-reaction with any of the pathogens tested.

Clinical Performance

Design of Primers and Probe for SARS-CoV-2 Detection
Using a primer and probe design tool, the assay primers and
probe speciﬁcally targeting the S gene of SARS-CoV-2
(Table 1) were designed to amplify a 108 bp target on the
conserved S gene based on multiple sequence alignments
and in silico analysis for the NWHL LDT primers and probe

4

A total of 270 clinical NP specimens were tested with the
NWHL LDT and the modiﬁed CDC assay at NWHL.
Overall, the NWHL LDT showed a percent positive
agreement of 98.5% (95% CI, 0.946e0.996) and a percent
negative agreement of 99.3% (95% CI, 0.961e0.999); the
overall percent agreement between both assays was 98.9%.
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A kappa value of 0.978 (95% CI, 0.953e1.0) indicated
perfect agreement (Table 4). For discordant results from
three specimens, two specimens were detected by the
modiﬁed CDC assay and were not detected by the NWHL
LDT; they had a Ct value of 37.3 for N1 and 39.6 for N2,
and 38.2 for N1 and 39.2 for N2, respectively. After a fresh
RNA extraction and retesting, the specimen with 37.3 N1
and 39.6 N2 Ct values was detected by both assays, and the
other specimen had a “not detected” result by both assays.
One specimen was initially detected by the NWHL LDT and
not by the modiﬁed CDC assay, exhibiting a Ct value of
32.0 on the LDT. After retesting, both the modiﬁed CDC
assay and the NWHL LDT assay results were positive.

Discussion
In the current study, a multiplex real-time RT-PCR assay
was developed and validated for SARS-CoV-2especiﬁc
detection in NP specimens on the 7500 Fast Dx Real-Time
PCR Instrument. The ﬁndings show that the NWHL LDT
has comparable clinical performance for the speciﬁc detection of SARS-CoV-2 RNA in NP specimens and is more
efﬁcient and cost-effective compared with the modiﬁed
CDC assay. Because the modiﬁed CDC assay has been
compared with multiple other commercially available
diagnostic assays and has equal or better performance, the
performance of the NWHL LDT would also show equivalent performance.6 The design also revealed signiﬁcant advantages over the modiﬁed CDC assay, as only one set of
primer and probe Master Mix is required to prepare and
dispense per specimen, in contrast to three sets of Master
Mix preparation and the use of three wells for each patient
specimen with the modiﬁed CDC assay. The multiplex
design of the NWHL LDT allows testing of 91 patients per
plate, versus a maximum of 29 patients per plate on the
modiﬁed CDC assay. Overall, this design allows laboratories to run more than three times as many patients per run
and also adds to the ease of setting up each run. In addition,
the saving of hands-on time, reagents, and consumables is
another advantage at a stage where there are currently global
shortages of reagents and major assay supply chain issues.
The design of the primers and probe for the NWHL LDT
is based on multiple sequence alignments of all SARS-CoV2 genome sequences that were available between January
11, 2020, and February 27, 2020. Because RNA viruses are
well known for their high mutation and recombination
rates,9 it was important to conﬁrm that there were no signiﬁcant new mutations of the region of the S gene of SARSCoV-2 targeted by the NWHL LDT that may affect assay
performance. Therefore, an additional 140 SARS-CoV-2
genome sequences uploaded after February 27, 2020, to
the GenBank database and the Global Initiative on Sharing
All Inﬂuenza Database from different countries were
analyzed, and an alignment was performed with Clustal
Omega. This alignment showed that the forward primer and
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probe are conserved (with 100% homology) to the S gene
target regions of the SARS-CoV-2 sequences. One exception
was seen with the reverse primer, a single base mismatch of S
gene target region in one sequence (GenBank, https://www.
ncbi.nlm.nih.gov/nuccore; accession number MT385417.1)
from a total of 240 SARS-CoV-2 sequences analyzed both
before and after late February. This one mismatch is questionable, because it is not in keeping with the other sequences
available; the databases are not curated and therefore occasionally contain errors. The Simplexa COVID-19 Direct
(DiaSorin Molecular LLC, Cypress, CA), which has US Food
and Drug Administration Emergency Use Authorization
approval for SARS-CoV-2, also targets the S gene and shows
a slightly lower LOD than the NWHL LDT in their Emergency Use Authorization instructions for use; however, the
material used for the Simplexa LOD study differed, making a
clear comparison difﬁcult.
Limitations of the current study include that the NWHL
LDT is a single-site evaluation at NWHL, and only a single
target gene for SARS-CoV-2 detection was used. Although
there has been a trend toward dual-target design in commercial assays for the detection of this highly contagious
pathogen,6,10,11 occasional monitoring of SARS-CoV-2 sequences to verify that mutations have not developed in the
region targeted by the NWHL LDT primers and probe is an
adequate quality monitor to ensure continued consistent
analytical performance. In addition, other targets may be
added to this assay in the future to further increase sensitivity and speciﬁcity. As an additional future plan, the
analytical sensitivity of the NWHL LDT may be improved
further by increasing the input volume and decreasing the
elution volume during the nucleic acid extraction step.
In summary, the NWHL LDT has comparable analytical
sensitivity and accuracy for speciﬁc detection of SARSCoV-2 RNA and also exhibits superior efﬁciency and costeffectiveness compared with the modiﬁed CDC assay. Other
laboratories may also be able to establish this assay with
ease for diagnostic use.
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